Loading...

Aditxt's Subsidiary Adimune Showcases Its Method for Immune System Reprogramming via DNA Instructions, Boasting 96 Granted and 22 Pending Patents Aimed at the Autoimmunity Market Projected to Exceed $160 Billion by 2030 | Intellectia.AI